GDC0152 is an investigational small molecule inhibitor primarily studied for its potential in cancer therapy. It functions by targeting key proteins involved in cell survival and proliferation pathways, particularly those implicated in tumor growth. The compound has been explored in preclinical and early clinical trials for its ability to induce apoptosis in cancer cells, especially in hematologic malignancies and solid tumors. Its application focuses on oncology research, where it serves as a tool compound to understand signaling pathways like NF-κB and their role in resistance to apoptosis. Due to its mechanism, GDC0152 has been evaluated for use in combination therapies, aiming to enhance the efficacy of other anticancer agents by overcoming drug resistance. Although development has been limited or discontinued in some cases, it remains relevant in research settings for validating therapeutic targets and optimizing inhibitor design in cancer treatment strategies.